Question

Briefly describe the drug inhaler Trelegy Ellipta in 500 words on how does it work, what is biological response, side effects, and pharmacokinetic parameters such as volume of depletion and half-life in your own words.

Answer 1

ANSWER:

TRELEGY ELLIPTA:

TRELEGY ELLIPTA IS AN INHALER WHICH CONTAINS COMBINATION OF THREE DRUGS NAMELY FLUTICASONE,UMECLIDINIUM ,AND VILANTEROL.IT IS THE DRUG WHICH IS USED TO CURE CHRONIC CONDITIONS LIKE CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD),BRONCHITIS AND EMPHYSEMA.IT SHOULD BE NOTED THAT IT SGHOULD NOT BE USED FOR THE TREATMENT OF ASTHMA.IT CONTAINS THREE LONG-DURATION ACTION MEDICINES : FLUTICASONE (100 mcg/DAY) WHICH IS AN INHALED CORTICOSTEROID HELPS IN CONTROL OF INFLAMMATION BY ACTING AGAINST THE SUBSTANCES THAT INITIATE INFLAMMATION.UMECLIDINIUM,(62.5 mcg/DAY)IS A LONG-ACTING MUSCARINIC ANTAGONIST (LAMA ) WHICH IS OTHERWISE CALLED AS ANTICHOLINERGIC.VILANTEROL (25 mcg/DAY)IS A LONG-ACTING BETA 2 -ADRENERGIC AGONIST (LABA) ,WHICH IS A BRONCHODILATOR. ALL THREE DRUGS IN A COMBINED WAY HELPS IN RELAXING OF THE MUSCLES AND DILATES THE BRONCHIOLES TO IMPROVE THE AIRWAY AND BREATHING.IT PREVENTS BRONCHOSPASM IN THE PATIENTS WITH COPD.IT IS A FDA-APPROVED ONCE-DAILY COPD MEDICATION .IT CONTAINS THREE DRUGS IN ONE INHALER.IT EFFICIENTLY WORKS FOR ONE WHOLE DAY.THE INHALER IS NOT EFFECTIVE TO RELIEVE SUDDEN SHORTNESS OF BREATH. TRELEGY IS CONTRAINDICATED IN ASTHMA, PATIENTS WHO ARE ALLERGIC TO ANY OF THESE THREE DRUGS, OR MILK PROTEINS.IT SHOULD BE USED IN THE SAME TIME EVERY DAY ORALLY BUT ONLY ONE DOSE IN 24 HOURS. IT REDUCES EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS.ANOTHER IMPORTANT PRECAUTION FOR THE USE OF THIS DRUG IS THAT IT MAY LEAD TO PARADOXICAL BRONCHOSPASM IMMEDIATELY AFTER THE ADMINISTRATION OF THE DRUG WHICH CAUSES WHEEZING AND SHORTNESS OF BREATH AND MAY BE LIFE-THREATENING.PEOPLE WITH UNSTABLE OR ANY OTHER CARDIAC CONDITIONS SHOULD USE IT WITH CAUTION AS IT MAY LEAD TO ARRHYTHMIAS AND ATRIAL FIBRILLATION WHICH MAY ENDANGER LIFE.